Peptide 'before and after' claims for autoimmune conditions: what the evidence says

What's this video probably claiming?

Based on the caption and hashtags, this creator is almost certainly showing visual or symptomatic improvement they attribute to peptide therapy, likely framing it as a personal recovery story tied to an autoimmune or chronic illness diagnosis. The #peptidejourney and #autoimmunedisease tags together are a well-worn combination on TikTok that typically leads to claims about peptides like BPC-157, TB-500, or GHK-Cu reducing inflammation, calming an overactive immune system, or accelerating healing in conditions like lupus, rheumatoid arthritis, or Crohn's disease. Before-and-after framing implies a causal relationship between peptide use and improvement, which is where things get scientifically complicated fast. Personal testimonials are compelling content. They are not clinical evidence. The creator may genuinely feel better, and that experience is real to them, but the jump from "I feel better" to "peptides fixed my autoimmune disease" carries significant evidentiary weight that a 60-second TikTok cannot responsibly support.

What does the science actually show?

The honest answer is: not much, at least not in humans with autoimmune conditions. BPC-157, arguably the most hyped peptide in this space, has an interesting rodent literature. Sikiric et al. (2018, Current Pharmaceutical Design) documented anti-inflammatory and gut-healing effects in rat models, but zero randomized controlled trials in humans exist for autoimmune indications. TB-500, a synthetic fragment of Thymosin Beta-4, shows wound-healing properties in animal models (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but again, human autoimmune data is absent. GHK-Cu has published work on tissue remodeling (Pickart et al., 2015, Journal of Aging Research), with some legitimate anti-inflammatory signaling activity in cell cultures. None of these peptides have completed Phase III trials. The FDA has not approved any of them for any indication. Calling them treatments for autoimmune disease based on current evidence is a significant overstep.

Where does the social media noise diverge from clinical reality?

The gap here is enormous and specific. Social media peptide content routinely presents animal model findings as if they translate directly to human outcomes, skips over the bioavailability problem entirely (oral peptides are largely degraded before systemic absorption; injectable routes carry their own risks), and ignores that autoimmune conditions are genuinely complex, often fluctuating diseases. Symptom remission happens naturally in many autoimmune conditions. A patient who starts a peptide during a flare and improves over eight weeks may simply be experiencing their disease's natural course. That is not a peptide success story; that is regression to the mean. The compounded peptide market also operates in a regulatory gray zone. The FDA issued guidance in 2023 restricting certain peptides including BPC-157 from compounding pharmacies as bulk substances, meaning purity, dosing accuracy, and sterility cannot be assumed. A before-and-after video cannot account for any of this.

What should you actually know?

If you have an autoimmune condition and you are considering peptides because a TikTok before-and-after moved you, here is what the actual clinical picture looks like. First, no peptide currently has regulatory approval for any autoimmune indication anywhere in the world. Second, the placebo effect in chronic illness is well-documented and substantial. Hrobjartsson and Gotzsche (2010, Cochrane Database) found meaningful placebo responses in subjective symptom outcomes across chronic conditions. Third, some peptides do interact with immune pathways, and in autoimmune patients whose immune systems are already dysregulated, that is not automatically beneficial. Fourth, the sourcing problem is real. Third-party testing of gray-market peptides has found dosing inaccuracies and contamination. Fifth, if a peptide genuinely has therapeutic potential for your condition, that potential deserves to be evaluated in a proper clinical setting with appropriate monitoring, not self-administered based on a content creator's anecdote. Talk to a licensed clinician before adding anything to an existing autoimmune treatment regimen.